Michael Kauffman
CIK 1364719 · President of Development · last filed 2026-06-17
Michael Kauffman is a President of Development who has filed 117 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for KYNB, was dated Jun 17, 2026. Across all open-market trades the lifetime net is −$20.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $824.9K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$824.9K
11
117
-$20.02M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYNB | Director | — | $6.97 | — | $0 | 1 | 2026-06-17 |
| Kezar Life Sciences, Inc. (KZR) Delisted | Director | 0 | $7.29 | $0 | -$82.2K | 11 | 2026-05-11 |
| VSTM | President of Development | 8,666 | $6.23 | $54.0K | -$51.8K | 19 | 2026-01-08 |
| KYNTRA BIO, INC. (FGEN) Delisted | Director | — | $9.75 | — | $0 | 1 | 2025-06-06 |
| NCNA | Director | — | $1.29 | — | $0 | 1 | 2024-08-23 |
| ACET | Director | 738 | $8.20 | $6.1K | -$8.4K | 5 | 2024-06-07 |
| KPTI | Chief Executive Officer | 107,874 | $7.09 | $764.8K | -$19.88M | 64 | 2022-03-02 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | — | $0.04 | — | $0 | 3 | 2019-06-14 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Chief Medical Officer | 9,000 | — | — | $0 | 2 | 2010-02-11 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Director | — | — | — | $0 | 3 | 2010-01-20 |
| BIOENVISION INC (BIVN) Delisted | Director | — | — | — | $0 | 1 | 2007-01-05 |
Recent Filings
117 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-17 | KYNB | Grant (A) | — | $0 | EDGAR |
| 2026-05-11 | Kezar Life Sciences, Inc. (KZR) Delisted | Mixed | −6,369 | $0 | EDGAR |
| 2026-01-08 | VSTM | Grant (A) | — | $0 | EDGAR |
| 2025-11-25 | VSTM | Sell (S) | −8,550 | -$85.5K | EDGAR |
| 2025-11-21 | VSTM | Notice (144) | −8,550 | -$83.9K | EDGAR |
| 2025-06-23 | Kezar Life Sciences, Inc. (KZR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | KYNTRA BIO, INC. (FGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-05-27 | VSTM | Grant (A) | +8,333 | $0 | EDGAR |
| 2024-08-23 | NCNA | Mixed | — | $0 | EDGAR |
| 2024-06-21 | Kezar Life Sciences, Inc. (KZR) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.